In another phase I study, EGFR-targeted CAR-T cell infusions were well tolerated without severe toxicity in patients with NSCLC, and of 11 patients, two had partial response and five had stable disease for up to 8 months (196) (Table 2). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.